博济医药：FCZR获得药物临床试验批准通知书

Core Viewpoint - Boji Pharmaceutical (300404) has received approval from the National Medical Products Administration for its clinical trial application for "FCZR," which is intended for the treatment of ear fungal disease [1] Company Summary - Boji Pharmaceutical announced on September 3 that it has obtained the clinical trial approval notice for "FCZR" from the National Medical Products Administration [1] - The proposed indication for FCZR is ear fungal disease [1]